Orly Lipsitz
PhD Candidate in Clinical Psychology at the University of Toronto
Data updated
Research Footprint
Orly Lipsitz appears in 9 tracked papers (2020–2026), most studied alongside Ketamine, Psilocybin and MDMA, across Depressive Disorders, Anxiety Disorders and Treatment-Resistant Depression (TRD).
Most-cited paper: Registered clinical studies investigating psychedelic drugs for psychiatric disorders (100 citations).
Frequent co-authors: Jonathan Rosenblat, Roger McIntyre and Maria Rodrigues.
Background & Research
Orly Lipsitz is a PhD candidate in Clinical Psychology at the University of Toronto, where she also completed her MA under the supervision of Dr. Anthony Ruocco. Her research focuses on neurocognition, psychopathology, and functional outcomes, with recent publications in ketamine and psilocybin-assisted therapy for treatment-resistant depression.
Key Impact
Orly Lipsitz is a clinical psychology researcher contributing to real-world ketamine and psilocybin studies in treatment-resistant depression, including work on cognitive outcomes, sleep, and predictors of response.
Collaboration Network
19 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Orly Lipsitz is associated with.
University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →Brain and Cognition Discovery Foundation
Non-ProfitCanada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.
View stakeholder →